The pharmacology of esomeprazole and its role in gastric acid related diseases

Expert Opinion on Drug Metabolism and Toxicology

Volumn 5, Issue 9, 2009, Pages 1113-1124

  Saccar, Consuelo L ^a  

^a Asthma and Allergy Research Associates   (United States)

Author keywords

Gastro esophagitis reflux disease; GERD; Long term efficacy and tolerability of esomeprazole compared to laparoscopic anti reflux surgery in adult subjects with gastroesophageal reflux disease; LOTUS; NASA; NERD; Nexium anti inflammatory symptom amelioration; Non erosive reflux disease; Non steroidal anti inflammatory drugs; NSAID; PLUTO; PPI; Prevention of latent ulceration treatment options; Proton pump inhibitor; SPACE; Symptom prevention by acid control with esomeprazole; VENUS; Verification of esomeprazole for NSAID ulcers and symptoms

Indexed keywords

ATAZANAVIR; CLOPIDOGREL; ESOMEPRAZOLE; INDINAVIR; LANSOPRAZOLE; LOPINAVIR; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PANTOPRAZOLE; PLACEBO; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE; ROFECOXIB; TIPRANAVIR;

ABDOMINAL PAIN; AREA UNDER THE CURVE; CLINICAL TRIAL; COUGHING; DIARRHEA; DIGESTIVE SYSTEM ULCER; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FLATULENCE; FUNDIC GLAND POLYP; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL SYMPTOM; HEADACHE; HELICOBACTER INFECTION; HUMAN; MYOPATHY; NAUSEA; PNEUMONIA; POLYP; REFLUX ESOPHAGITIS; RESPIRATORY TRACT INFECTION; REVIEW; STOMACH ACID SECRETION; ZOLLINGER ELLISON SYNDROME;

CLINICAL TRIALS AS TOPIC; DRUG INTERACTIONS; GASTROINTESTINAL DISEASES; HUMANS; OMEPRAZOLE;

HELICOBACTER PYLORI;

EID: 70249136545     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425250903124363     Document Type: Review

References (97)

1. Shi S, Klotz U. Proton pump inhibitors: an update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol 2008;64:935-951
2. McKeage K, Blick SKA, Croxtall JD, et al. Esomeprazole a review of its use in the management of gastric acid-related diseases in adults. Drugs 2008;68(11):1571-1607 (Pubitemid 352001193)
3. Scott LJ, Dunn CJ, Mallarkey G, et al. Esomeprazole: a review of its use in management of acid-related disorders. Drugs 2002;62(10):1503-1538 (Pubitemid 34804157)
4. Sachs G, Shin JM, Howden CW. Review article: the clinical pharmacology of proton pump inhibitors. Aliment Pharmacol Ther 2006;23(Suppl 2):2-8 (Pubitemid 44383831)
5. Hellström PM, Vitols S. The choice of proton pump inhibitor: does it matter? Clin Pharmacol Toxicol 2004;94:106-111
6. Kirchheiner J, Glatt S, Fuhr U, et al. Relative potency of proton-pump inhibitors - comparison of effects on intragastric pH. Eur J Clin Pharmacol 2009;65:19-31
7. Wilder-Smith C, Lind T, Lundin C, et al. Acid control with esomeprazole and lansoprazole: a comparative dose-response study. Scand J Gastroenterol 2007;42:157-164 (Pubitemid 46253860)
8. Li XQ, Andersson TB, Ahlstrom M, et al. Comparison of inhibitory effects of the proton pump-inhibiting drugs Omeprazole, Esomeprazole, Lansoprazole, Pantoprazole, and Rabeprazole on human cytochrome P450 activities. Drug Metab Dispos 2004;32:821-1745 (Pubitemid 38955611)
9. Horn JR, Howden CW. Review article: similarities and differences among delayed-release proton-pump inhibitor formulations. Aliment Pharmacol Ther 2005;22(Suppl 3):20-24 (Pubitemid 41783983)
10. Andersson T, Rohss K, Bredberg E, et al. Pharmocokinetics and pharmacodynamics of esomeprazole, the s-isomer of omeprazole. Aliment Pharmacol Ther 2001;15:1563-1569 (Pubitemid 32912398)
11. Hassan-Alin M, Andersson T, Bredberg E, et al. Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects. Eur J Clin Pharmacol 2000;56:665-670 (Pubitemid 32204486)
12. Lind T, Rydberg L, Kyleback A, et al. Esomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2000;14:861-867 (Pubitemid 30446896)
13. Sostek M, Chen Y, Andersson T. Effect of timing of dosing in relation to food intake on the pharmacokinetics of esomeprazole. Br J Clin Pharmacol64(3):386-390
14. Bladh N, Blychert E, Johansson K, et al. A new esomeprazole packet (Sachet) formulation for suspension: in vitro characteristics and comparative pharmacokinetics versus intact capsules/ tablets in healthy volunteers. Clin Ther29(4):640-649
15. Omari T, Davidson G, Bondarov P, et al. Pharmacokinetics and Acid-suppressive effects of esomeprazole in infants 1-24 months old with symptoms of gastroesophageal reflux disease. JPGN 2007;45:530-537 (Pubitemid 350307137)
16. Zhao J, Jianguo L, Hamer-Maansson JE, et al. Pharmacokinetic properties of esomeprazole in children aged 1 to 11 years with symptoms of gastroesophageal reflux disease: a randomized, open-label study. Clin Ther 2006;28(11):1868-1876 (Pubitemid 46043511)
17. Jianguo L, Zhao J, Hamer-Maansson JE, et al. Pharmacokinetic properties of esomeprazole in adolescent patients aged 12 to 17 years with symptoms of gastroesophageal reflux disease: a randomized, open-label study. Clin Ther 2006;28(3):419-427 (Pubitemid 44208780)
18. Abelo A, Andersson T, Antonsson M, et al. Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes. Drug Metab Dispos 2000;28(8):966-972 (Pubitemid 30612617)
19. Schwab M, Klotz U, Hofmann U, et al. Esomeprazole-induced healing of gastroesophageal reflux disease is unrelated to the genotype of CYP2C19: evidence from clinical and pharmacokinetic data. Clin Pharmacol Ther 2005;78:627-634 (Pubitemid 41773638)
20. Andersson T, Hassan-Alin M, Hasselgren G, et al. Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole. Clin Pharmacokinet 2001;40(6):411-426 (Pubitemid 32656078)
21. Klotz U. Pharmacokinetic considerations in the eradication of helicobacter pylori. Clin Pharmacokinet 2000;38(3):243-270 (Pubitemid 30156624)
22. Hasselgren G, Hassan-Alin M, Andersson T, et al. Pharmacokinetic study of esomeprazole in the elderly. Clin Pharmacokinet 2001;40(2):145-150
23. Naesdal J, Andersson T, Bodemar G, et al. Pharmacokinetics of [14C] omeprazole in patients with impaired renal function. Clin Pharmacol Ther 1986;40(3):344-351 (Pubitemid 16017863)
24. Sjovall H, Bjornsson E, Holmberg J, et al. Pharmacokinetic study of esomeprazole in patients with hepatic impairment. Eur J Gastroenterol Hepatol 2002;14(5):491-496 (Pubitemid 34518180)
25. Miner P, Katz PO, Chen Y, et al. Gastric acid control with Esomeprazole, Lansoprazole, Omeprazole, Pantoprazole and Rabeprazole: a five-way crossover study. Am J Gastroenterol 2003;98(2):2616-2620 (Pubitemid 38020098)
26. Bardhan KD, Achim A, Riddermann T, et al. A clinical trial comparing pantoprazole and esomeprazole to explore the concept of achieving 'complete remission' in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2007;25(12):1461-1469
27. Castell DO, Kahrilas PJ, Richter JE, et al. Esomeprazole (40mg) compared with lansoprazole (30mg) in the treatment of erosive esophagitis. Am J Gastroenterol 2002;97(3):575-583
28. Fennerty MB, Johanson JF, Hwang C, et al. Efficacy of esomeprazole 40mg vs. lansoprazole 30mg for healing moderate to severe erosive oesophagitis. Aliment Pharmacol Ther 2005;21(4):455-463 (Pubitemid 40313949)
29. Gillessen A, Beil W, Modlin IM, et al. 40mg pantoprazole and 40mg esomeprazole are equivalent in the healing of esophageal lesions and relief from gastroesophageal reflux disease-related symptoms. J Clin Gastroenterol 2004;38(4):332-340 (Pubitemid 38393069)
30. Howden CW, Ballard II ED, Robieson W. Evidence for therapeutic equivalence of lansoprazole 30mg and esomeprazole 40mg in the treatment of erosive oesophagitis. Clin Drug Invest 2002;22(2):99-109 (Pubitemid 34158093)
31. Labenz J, Armstrong D, Lauritsen K, et al. A randomized comparative study of esomeprazole 40mg versus pantoprazole 40mg for healing erosive oesophagitis: the EXPO study. Aliment Pharmacol Ther 2005;21(6):739-746 (Pubitemid 40476079)
32. Lightdale CJ, Schmitt C, Hwang C, et al. A multicenter, randomized, double-blind, 8-week comparative trial of low-dose esomeprazole (20mg) and standard-dose omeprazole (20mg) in patients with erosive esophagitis. Dig Dis Sci 2006;51(5):852-857 (Pubitemid 44030802)
33. Schmitt C, Lightdale CJ, Hwang C, et al. A multicenter, randomized, double-blind, 8-week comparative trial of standard doses of esomeprazole (40mg) and omeprazole (20mg) for the treatment of erosive esophagitis. Dig Dis Sci 2006;51(5):844-850 (Pubitemid 44030800)
34. Kahrilas PJ, Falk GW, Johnson DA, et al. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. Aliment Pharmacol Ther 2000;14(10):1249-1258
35. Richter JE, Kahrilas PJ, Johanson J, et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol 2001;96:656-665 (Pubitemid 32240711)
36. Edwards SJ, Lind T, Lundell L. Systematic review: proton pump inhibitors (PPIs) for the healing of reflux oesophagitis - a comparison of esomeprazole with other PPIs. Aliment Pharmacol Ther24:743-750
37. Gralnek IM, Dulai GS, Fennerty MB, et al. Esomeprazole versus other proton pump inhibitors in erosive esophagitis: a meta-analysis of randomized clinical trials. Clin Gastroenterol Hepatol 2006;4:1452-1458
38. Sheu BS, Chang WL, Cheng HC, et al. Body mass index can determine the healing of reflux esophagitis with Los Angeles grades C and D by esomeprazole. Am J Gastroenterol 2008;103:2209-2214
39. De Vault KR, Johanson JF, Johnson DA, et al. Maintenance of healed erosive esophagitis: a randomized six-month comparison of esomeprazole twenty milligrams with lansoprazole fifteen milligrams. Clin Gastroenterol Hepatol 2006;4(7):852-859
40. Lauritsen K, Deviere J, Bigard MA, et al. Esomeprazole 20mg and lansoprazole 15mg in maintaining healed reflux oesophagitis: metropole study results. Aliment Pharmacol Ther 2003;17(3):333-341 (Pubitemid 36259395)
41. Johnson DA, Banjamin SB, Vakil NB, et al. Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety. Am J Gastroenterol 2001;96(1):27-34
42. Vakil NB, Shaker R, Johnson DA, et al. The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: a 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety. Aliment Pharmacol Ther 2001;15(7):927-935 (Pubitemid 32578963)
43. Goh KL, Benamouzig R, Sander P, et al. Efficacy of pantoprazole 20 mg daily compared with esomeprazole 20 mg daily in the maintenance of healed gastroesophageal reflux disease: a randomized, double-blind comparative trial - the EMANCIPATE study. Eur J Gastroenterol Hepatol19:205-211
44. Labenz J, Armstrong D, Lauritsen K, et al. Esomeprazole 20mg vs. pantoprazole 20mg for maintenance therapy of healed erosive oesophagitis: results from the EXPO study. Aliment Pharmacol Ther 2005;22(9):803-811 (Pubitemid 41564360)
45. Galmiche JP. EMANCIPATE study: drawing conclusions may be difficult in the absence of fundamental information. Eur J Gastroenterol Hepatol 2008;20(2):151-152
46. Labenz J. EMANCIPATE versus EXPO: different results can be explained by differing study designs. Eur J Gastroenterol Hepatol 2008;20(2):152
47. Maton PN, Vakil NB, Levine JG, et al. Esomeprazole Study Investigators. Safety and efficacy of long-term esomeprazole therapy in patients with healed erosive oesophagitis. Drug Saf 2001;24:625-635
48. Sjostedt S, Befrits R, Sylvan A, et al. Daily treatment with esomeprazole is superior to that taken on-demand for maintenance of healed erosive oesophagitis. Aliment Pharmacol Ther 2005;22(3):183-191 (Pubitemid 41153060)
49. Lundell L, Attwood S, Ell C, et al. Comparing laparoscopic anti-reflux surgery to esomeprazole in the management of patients with chronic gastro-oesophageal reflux disease: a 3-year interim analysis of the LOTUS trial. Gut [Epub 2008 May]
50. Lundell L, Attwood S, Ell C, et al. Comparing laparoscopic antireflux surgery with Esomeprazole in the management of patients with chronic gastro-oesophageal reflux disease: a 3-year interim analysis of the LOTUS trial. Gut 2008;57:1207-1213
51. Attwood SE, Lundell L, Hatlebakk JG, et al. Medical or surgical management of GERD patients with Barrett's Esophagus: the LOTUS trial 3-year experience. J Gastrointest Surg 2008;12:1646-1655
52. Armstrong D, Talley NJ, Lauritsen K, et al. The role of acid suppression in patients with endoscopy-negative reflux disease: the effect of treatment with esomeprazole or omeprazole. Aliment Pharmacol Ther 2004;20(4):413-421 (Pubitemid 39120252)
53. Katz PO, Castell DO, Levine D. Esomeprazole resolves chronic heartburn in patients without erosive esophagitis. Aliment Pharmacol Ther 2003;18(9):875-882 (Pubitemid 37346672)
54. Tsai HH, Chapman R, Shepherd A, et al. Esomeprazole 20mg on-demand is more acceptable to patients than continuous lansoprazole 15mg in the long-term maintenance of endoscopy-negative gastro-oesophageal reflux patients: the COMMAND Study. Aliment Pharmacol Ther 2004;20(6):657-665 (Pubitemid 39279054)
55. Talley NJ, Venables TL, Green JR, et al. Esomeprazole 40mg and 20 mg is efficacious in the long-term management of patients with endoscopy-negative gastro-oesophageal reflux disease: a placebo-controlled trial of on-demand therapy for 6 months. Eur J Gastroenterol Hepatol 2002;14(8):857-863
56. Talley NJ, Lauritsen K, Tuntunri-Hihnala H, et al. Esomeprazole 20mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of on demand therapy for 6 months. Aliment Pharmacol Ther 2001;15(3):347-354 (Pubitemid 32187556)
57. Fock KM, Teo EK, Ang TL, et al. Rabeprazole vs esomeprazole in non-erosive gastro-esophageal reflux disease a randomized, double-blind study in urban Asia. World J Gastroenterol 2005;11:3091-3098
58. Pace F, Tonini M, Pallota S, et al. Systematic review: maintenance treatment of gastro-oesophageal reflux disease with proton pump inhibitors taken 'on-demand'. Aliment Pharmacol Ther 2007;26:195-204
59. Metz DC, Inadomi JM, Howden CW, et al. On-demand therapy for gastroesophageal reflux disease. Am J Gastroenterol 2007;102:642-653 (Pubitemid 46328170)
60. The American Lung Association Asthma Clinical Research Centers. Efficacy of Esomeprazole for treatment of poorly controlled asthma. N Eng J Med 2009;360(15):1487-1499
61. Tulassay Z, Kryszewski A, Dite P, et al. One week of treatment with esomeprazole-based triple therapy eradicates Helicobacter pylori and heals patients with duodenal ulcer disease. Eur J Gastroenterol Hepatol 2001;13(12):1457-1465 (Pubitemid 33151498)
62. Wu IC, Wu DC, Hsu PI, et al. Rabeprazole versus esomeprazole based eradication regiments for H. pylori infection. Helicobacter 2007;12(6):633-637
63. Veldhuyzen van Zanten S, Lauritsen K, Delchier J-C, et al. One-week triple therapy with esomeprazole provides effective eradication of Helicobacter pylori in duodenal ulcer disease. Aliment Pharmacol Ther 2000;14(12):1605-1611 (Pubitemid 32012433)
64. Veldhuyzen van Zanten S, Machado S, Lee J. One-week triple therapy with esomeprazole, clarithromycin and metronidazole provides effective eradication of Helicobacter pylori infection. Aliment Pharmacol Ther 2003;17(11):1381-1387 (Pubitemid 36774145)
65. Laine L, Fennerty B, Osato M, et al. Esomeprazole-based Helicobacter pylori eradication therapy and the effect of antibiotic resistance: results of three US multicenter, double-blind trials. Am J Gastroenterol 2000;95(12):3393-3398
66. Hsu PI, Lai KH, Wu CJ, et al. High-dose versus low-dose esomeprazole-based triple therapy for Helicobacter pylori infection. Eur J Clin Invest 2007;37(9):724-730 (Pubitemid 47256175)
67. Hsu PI, Lai KH, Lin CK, et al. A prospective randomized trial of esomeprazole versus pantoprazole-based triple therapy for Helicobacter pylori eradication. Am J Gastroenterol 2005;100(11):2387-2392 (Pubitemid 43919666)
68. Subei IM, Cardona HJ, Bachelet E, et al. One week of esomeprazole triple therapy vs 1 week of omeprazole triple therapy plus 3 weeks of omeprazole for duodenal ulcer healing in Helicobacter pylori-positive patients. Dig Dis Sci 2007;52(6):1505-1512 (Pubitemid 46776496)
69. Tulassay Z, Stolte M, Sjolund M, et al. Effect of esomeprazole triple therapy on Helicobacter pylori eradication rates, gastric ulcer healing, and prevention of relapse in gastric ulcer patients. Eur J Gastroenterol Hepatol 2008;20(6):526-536 (Pubitemid 351667893)
70. Sung JJY, Barkun A, Kuipers E, et al. Intravenous Esomeprazole for prevention of recurrent peptic ulcer bleeding. Ann Intern Med 2009;150:455-464
71. Morgner A, Michlke S, Labenz J. Esomeprazole: prevention and treatment of NSAID-induced symptoms and ulcers. Expert Opin Phamacother 2007;8(7):975-988 (Pubitemid 351227485)
72. Laine L. The gastrointestinal effects of nonselective NSAIDS and COX-2-selective inhibitors. Semin. Arthritis Rheum 2002;32:25-32 (Pubitemid 36055618)
73. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. N Engl J Med 1999;340:1888-1899 (Pubitemid 29272670)
74. Goldstein JL, Johanson JF, Hawkey CJ, et al. Clinical trial: healing of NSAID-associated gastric ulcers in patients continuing NSAID therapy - a randomized study comparing ranitidine with esomeprazole. Aliment Pharmacol Ther 2007;26(8):1101-1111
75. Goldstein JL, Johanson JF, Suchower LJ, et al. Healing of gastric ulcers with esomeprazole versus ranitidine in patients who continued to receive NSAID therapy: a randomized trial. Am J Gastroenterol 2005;100(12):2650-2657
76. Hansen JM, Hallas J, Lauritsen JM, et al. Non-steroidal anti-inflammatory drugs and ulcer complications: a risk factor analysis for clinical decision-making. Scand J Gastroenterol 1996;31:126-130 (Pubitemid 26047042)
77. Scheiman JM, Yeomans ND, Talley NJ, et al. Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. Am J Gastroenterol 2006;101(4):701-710
78. Hawkey C, Talley NJ, Yeomans ND, et al. Improvements with esomeprazole in patients with upper gastrointestinal symptoms taking non-steroidal anti-inflammatory drugs, including selective COX-2 inhibitors. Am J Gastroenterol 2005;100(5):1028-1036 (Pubitemid 40769038)
79. Hawkey CJ, Talley NJ, Scheiman JM, et al. Maintenance treatment with esomeprazole following initial relief of non-steroidal anti-inflammatory drug-associated upper gastrointestinal symptoms: the NASA2 and SPACE2 studies. Arthritis Res Ther 2007;9(1):R17
80. Yeomans N, Lanas A, Labenz J, et al. Prevention of low dose aspirin-associated gastroduodenal ulcers and upper gastrointestinal symptoms in patients receiving esomeprazole 20mg per day [abstract no. P2307]. Eur Heart J 2006;27(Suppl 1):382
81. Metz DC, Sostek MB, Ruszniewski P, et al. Effects of esomeprazole on acid output in patients with Zollinger-Ellison syndrome or idiopathic gastric acid hypersecretion. Am J Gastroenterol 2007;102(12):2648-2654 (Pubitemid 350179329)
82. Siller-Matula J, Spiel AO, Lang IM, et al. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J 2009;157:148.e1-5
83. Hassan-Alin M, Naesdal J, Nilsson-Pieschel C, et al. Lack of Pharmacokinetic interaction between esomeprazole and the nonsteroidal anti-inflammatory drugs naproxen and rofecoxib in healthy subjects. Clin Drug Investig 2005;25(11):731-740 (Pubitemid 41577413)
84. Falcon RW, Kakuda TN. Drug interactions between HIV protease inhibitors and acid-reducing agents. Clin Pharmacokinet 2008;47(2):75-89
85. McCabe SM, Smith PF, Ma Q, et al. Drug interactions between proton pump inhibitors and antiretroviral drugs. Expert Opin Drug Metab Toxicol 2007;3(2):197-207 (Pubitemid 47321516)
86. Shelton MJ, Ford SL, Borland J, et al. Coadministration of esomeprazole with fosamprenavir has no impact on steady-state plasma amprenavir pharmacokinetics. J Acquir Immune Defic Syndr 2006;42(1):61-67 (Pubitemid 43947947)
87. Castell DO, Kahrilas PJ, Richter JE, et al. Esomeprazole (40mg) compared with lansoprazole (30mg) in the treatment of erosive esophagitis. Am J Gastroenterol 2002;97(3):575-583
88. Genta RM, Rindi G, Fiocca R, et al. Effects of 6-12 months of esomeprazole treatment on the gastric mucosa. Am J Gastroenterol 2003;98:1257-1265 (Pubitemid 36741519)
89. US FDA Center for Drug Evaluation and Research. Early communication about an ongoing safety review: omeprazole (Prilosec) and esomeprazole (Nexium) [online]. Available from: http://www.fda. gov/CDER/Drug/early-comm/ omeprazole-esomeprazole.htm [Accessed 31 March 2009]
90. Clark DW, Strandell J. Myopathy including polymyositis: a likely class adverse effect of proton pump inhibitors. Eur J Clin Pharmacol 2006;62:473-479 (Pubitemid 43873719)
91. Caboni S, Gunera-Saad N, Ktiouet-Abassi S, et al. Esomeprazole-induced DRESS syndrome. Studies of cross-reactivity among proton-pump inhibitor drugs. Allergy 2007;62:1342-1343
92. Yang YX, Lewis JD, Epstein S, et al. Long-term pump inhibitor therapy and risk of hip fracture. JAMA 2006;296(24):2947-2953 (Pubitemid 46021498)
93. Jalving M, Koornstra JJ, Wesseling J, et al. Increased risk of fundic gland polyps during long-term proton pump inhibitor therapy. Aliment Pharmacol Ther 2006;24:1341-1348 (Pubitemid 44571564)
94. Martin de Argila C. Safety of potent gastric acid inhibition. Drugs 2005;65(Suppl 1):97-104 (Pubitemid 43057236)
95. Estborn L, Joelson S. Occurrence of community-acquired respiratory tract infection in patients receiving esomeprazole: retrospective analysis of adverse events in 31 clinical trials. Drug Saf 2008;31(7):627-636 (Pubitemid 351861955)
96. Johnson D. Review of esomeprazole in the treatment of acid disorders. Expert Opin Pharmacother 2003;4(2):253-264 (Pubitemid 36240465)
97. Kalaitzakis E, Bjornsson E. A review of esomeprazole in the treatment of gastroesophageal reflux disease (GERD). Ther Clin Risk Manage 2007;3(4):653-663 (Pubitemid 47496969)